Intelligent Bio Solutions Completes Key Clinical Study, Advances FDA 510(k) Path for Drug Screening System
Summary
Intelligent Bio Solutions Inc. has successfully completed its initial clinical Cut-off Study for its Intelligent Fingerprinting Drug Screening System, a critical milestone in its FDA 510(k) clinical program for codeine detection. This advancement moves the company closer to commercializing its non-invasive technology in the multi-billion-dollar U.S. drug screening market. For a company of INBS's size, this progress is highly material, offering a significant potential revenue stream that could help address the "going concern" warning noted in recent financial filings. The company will now proceed with multi-site Method Comparison, Usability, and Interference Studies, with completion anticipated by July 2026, which will be key catalysts to monitor.
At the time of this announcement, INBS was trading at $3.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2M. The 52-week trading range was $2.86 to $24.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.